China Hepatitis C Elimination
Alliance Public Welfare Project Started in Hengyang on April 20. More than 80
healthcare workers including leaders of county CDCs in Hengyang, professionals
of hepatitis C prevention and control, hospital leaders, infectious department
directors and liver disease department directors participated in the training
session. Five municipal medical institutions including Hengyang CDC, The First
and Second Affiliated Hospital and Affiliated Nanhua Hospital of University of
South China, Hengyang Central Hospital
and Hengyang Third People’s Hospital were conferred the plaques of “prevention and control base” “diagnosis and treatment base” of China Hepatitis C Elimination Alliance Public
Welfare Project. The project aims to cooperate to eliminate hepatitis C through
cooperation of medical institutions in Hengyang. Under
the guidance of Disease Control Division of Hunan Health Commission,the work of
hepatitis C elimination in Hengyang was jointly organized and implemented by
China Liver Health together with Hunan CDC, Hunan AIDS/STD Association,Hengyang
Health Commission and Hengyang CDC. Academician Zhuang Hui, honorary
chairman of China Liver Health, Li Jian, director of the National Center for
AIDS/STD Control and Prevention of China CDC, Shen Yingsheng, deputy director
of China Liver Health, Xie Ying, deputy director of Disease Control Division of Hunan Health Commission,
director He Jianmei and deputy director Zheng Jun from the Center for AIDS/STD
Control and Prevention of Hunan CDC, Zou Jianjun, director of Hengyang Health
Commission,Li Zhiyong, chief of the disease control and prevention section of
Hengyang Health Commission, Peng Weixiong, director of Hengyang CDC, Ren Qiong,chief
of the Center for AIDS/STD Control and Prevention of Hengyang CDC and other
leaders and experts from related hospitals attended the meeting. Chen Xi, deputy
director of Hunan CDC presided over the project startup and training meeting. Gilead Sciences provided public welfare support.
Medical institutions of
Hengyang cooperated to deal with the silent killer-hepatitis C Launched in
the Great Hall of the People in Beijing in 2017, China Hepatitis C Elimination
Alliance Public Welfare Project is committed to carrying out a series of public
welfare activities under the guidance of the Ministry of Civil Affairs, Bureau
of Disease Prevention and Control of National Health Commission,China CDC and WHO.
Xie Ying, deputy director of Disease Control Division of Hunan
Health Commission delivered a speech and pointed that
eliminating hepatitis C was one of the major tasks in implementing Healthy
China 2030 plan. By integrating social resources, the implementation of China
Hepatitis C Elimination Alliance Public Welfare Project in Hengyang, Hunan
province was an effective attempt for infectious disease prevention and
control. She hoped that the local CDCs, hospitals and health centers cooperate
actively to promote hepatitis C screening, detection and prevention, and
achieve eliminating hepatitis C in Hengyang as soon as possible. Zhuang Hui, academician
of Chinese Academy of Engineering,honorary
chairman of China Liver Health,general
counsel of China
Hepatitis C Elimination Alliance Public Welfare Project interpreted the burden of hepatitis C disease. Li Jian, director of the
National Center for AIDS/STD Control and Prevention of China CDC interpreted
the current situation of the hepatitis C epidemic in China. Viral
hepatitis C is a class B infectious disease stipulated in the Law of China on the Prevention and Control of Infectious Diseases.
Hepatitis C virus(HCV) is transmitted by blood and sexuality. In China, there
are 10 million people infected with HCV. 70% of them have not been detected and effectively treated, which is a
potential threat to their families and the society. Hepatitis C, known as a
silent killer because of the insidious onset, can progress to severe diseases
such as cirrhosis, and liver cancer. Hepatitis C can be completely cured with
oral direct-acting antivirals (DAAs). These drugs have been included in the medical
insurance of China. Drug prices have fallen by 85% since 2019, and treatment
expenses have been greatly reduced. Shen Yingsheng, deputy director of China
Liver Health introduced that, in order to improve the screening rate, detection
rate and treatment rate of hepatitis C in Hengyang, relying on one prevention
and control base and 5 diagnosis and treatment bases, China Hepatitis C
Elimination Alliance Public Welfare Project in Hengyang will focus on two
aspects.The first is to actively implement community publicity and training of
primary-level doctors and nurses, and improve the acquaintance of people at
high risk of hepatitis C infection, hepatitis C infected people, and
primary-level doctors and nurses on the harm of hepatitis C, detection and
treatment means, and medical insurance reimbursement policies. The second is to
promote the screening management process of hepatitis C combined with the daily
medical work of base hospitals, and promote the combination of the management
department, clinical department, laboratory department and infection control department
in medical institutions, strengthen the consultation and referral of infected
hepatitis C persons, and promote the diagnosis and treatment of hepatitis C
patients.
Entrusted by China Liver Health,
Chen Xi, deputy director of Hunan CDC announced to award Hengyang CDC
the title of prevention and treatment base of China Hepatitis C Elimination
Alliance Public Welfare Project, award The First and Second Affiliated Hospital and Affiliated Nanhua Hospital of
University of South China,Hengyang
Central Hospital and Hengyang Third People’s Hospital the title of diagnosis and treatment base of China Hepatitis C Elimination
Alliance Public Welfare Project, and to grant related experts as members of the
National Expert Committee for Liver Health Promotion.
Xie Ying, deputy director of Disease Control Division of Hunan Health Commission, Chen Xi, deputy director of Hunan CDC, Zou Jianjun, director of Hengyang Health Commission, Peng Weixiong, director of Hengyang CDC,He Jianmei, director of the Center for AIDS/STD Control and Prevention of Hunan CDC,Li Zhiyong,director of Disease Control Division of Hengyang Health Commission conferred plaques and certificates to relevant institutions and experts. The China Hepatitis C Elimination Alliance Public Welfare Project is sponsored by China Liver Health and co-organized by the Research Center of Infectious Diseases of Peking University, Chinese Foundation for Hepatitis Prevention and Control,Peking University Hepatology Institute, Chinese Society of Hepatology of Chinese Medical Association, Chinese Society of Infectious Diseases of Chinese Medical Association, Hepatology Institute of Jilin Province, Virtual Community of Hepatitis C, and Health Times of People’s Daily. Prof. Wei Lai, chairman of China Liver Health, served as the chief expert. Since the launch of the project, it has established cooperation with more than 140 medical and disease control institutions across the country, trained more than 4,000 medical workers onsite, and more than 100,000 online, and carried out more than 80,000 free screening cases. |
关注官方微信 
